Source - RNS
RNS Number : 6083K
Oxford Biomedica PLC
11 April 2018







Director Dealings / Market Share Purchase


Oxford, UK - 11 April 2018: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, today announces that Vulpes Testudo Fund, a person closely associated with Martin Diggle, Non-Executive Director, has purchased 1,000,000 ordinary shares of 1p each ("Ordinary Shares") in the Company on 10 April 2018 on the London Stock Exchange at a price of 11.0p per share. Following this purchase Vulpes Testudo/Vulpes Life Sciences Fund holds 582,008,434 ordinary shares representing 17.7% of the Company.


The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares purchased.




Details of the person discharging material responsibilities/person closely                 associated




 Vulpes Testudo Fund



Reason for the notification




 Person closely associated with Martin Diggle, Non-Executive Director


Initial notification /amendment

 Initial notification



Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor




 Oxford BioMedica plc



Legal Entity Identifier




Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted



Description of the financial instrument, type of instrument identification code

 Oxford BioMedica plc Ordinary Shares of 1p each






Nature of the transaction

 Purchase of ordinary shares




 GBP - British Pound



Price(s) and volume(s)













Aggregated information

·      Aggregated volume

·      Price

·      Aggregated total









Date of the transaction




Place of the transaction

 London Stock Exchange, Main Market (XLON)




The issued share capital of the Group is 3,283,790,680 ordinary 1p shares.                   






For further information, please contact:



Oxford BioMedica plc:

John Dawson,  Chief Executive Officer

Stuart Paynter, Chief Financial Officer


Tel: +44 (0)1865 783 000


Financial and corporate communications enquiries:

Consilium Strategic Communications

Mary-Jane Elliott/Matthew Neal/Philippa Gardner/Laura Thornton



Tel: +44 (0)20 3709 5700


Notes for editors


About Oxford BioMedica

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, GSK, Orchard Therapeutics, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 320 people. Further information is available at

This information is provided by RNS
The company news service from the London Stock Exchange